Dr. Ian Peter Thrippleton is a senior biotechnology executive with over four decades of leadership in diagnostics, water purification, and molecular technologies. He has served as Chief Technical Officer at NemDx Inc., guiding assay development and technology strategy. His prior roles include UK Manager for Hartmann Analytic GmbH, Managing Director of KIT Science & Service Ltd, and consultant to Aqua Cura and David Technologies, where he implemented cost‑efficient methods for removing toxic metals and pathogenic organisms from water and air. From 2006 to 2011 he was COO of Miacom Diagnostics GmbH, advancing rapid molecular pathogen characterization and contributing patent‑defining technologies. Earlier, as CEO of Creatogen AG and Managing Director of Creatogen Biosciences GmbH, he built a venture‑funded infectious‑disease diagnostics and vaccine platform company, raising DM 18M and leading a team of 35 scientists. His career began in product and business management roles at Difco Laboratories, Instrumentation Laboratory, Becton Dickinson, and Amersham‑Buchler, where he launched multiple biomedical product lines and coordinated international R&D and commercial operations. Dr. Thrippleton earned his Dr. rer. nat. in biochemistry at the Max‑Planck‑Institut für experimentelle Medizin, Göttingen, with earlier training in microbiology, bacterial physiology, and biochemistry at the Universities of Marburg and Göttingen. He brings deep expertise in diagnostic market development.
Dr. Ian Peter Thrippleton is a senior biotechnology executive with over four decades of leadership in diagnostics, water purification, and molecular technologies. He has served as Chief Technical Officer at NemDx Inc., guiding assay development and technology strategy. His prior roles include UK Manager for Hartmann Analytic GmbH, Managing Director of KIT Science & Service Ltd, and consultant to Aqua Cura and David Technologies, where he implemented cost‑efficient methods for removing toxic metals and pathogenic organisms from water and air. From 2006 to 2011 he was COO of Miacom Diagnostics GmbH, advancing rapid molecular pathogen characterization and contributing patent‑defining technologies. Earlier, as CEO of Creatogen AG and Managing Director of Creatogen Biosciences GmbH, he built a venture‑funded infectious‑disease diagnostics and vaccine platform company, raising DM 18M and leading a team of 35 scientists. His career began in product and business management roles at Difco Laboratories, Instrumentation Laboratory, Becton Dickinson, and Amersham‑Buchler, where he launched multiple biomedical product lines and coordinated international R&D and commercial operations. Dr. Thrippleton earned his Dr. rer. nat. in biochemistry at the Max‑Planck‑Institut für experimentelle Medizin, Göttingen, with earlier training in microbiology, bacterial physiology, and biochemistry at the Universities of Marburg and Göttingen. He brings deep expertise in diagnostic market development.